NLM-001
Idiopathic Pulmonary Fibrosis (IPF)
Phase 1Active
Key Facts
About Nelum Pharma
Nelum Pharma is a private, pre-revenue biotech focused on fibrosis and oncology. Its core asset is NLM-001, a potentially best-in-class hedgehog inhibitor in-licensed from Takeda (formerly TAK-441), which has demonstrated a favorable safety and pharmacokinetic profile in early clinical trials involving 60 patients. The company is led by a team of serial entrepreneurs and supported by a distinguished scientific advisory board, aiming to advance NLM-001 in idiopathic pulmonary fibrosis, a disease with high mortality and limited treatment options.
View full company profileOther Idiopathic Pulmonary Fibrosis (IPF) Drugs
| Drug | Company | Phase |
|---|---|---|
| OATD-01 | Molecure | Phase II |
| FP-020 (BMS-986235) | Foresee Pharmaceuticals | Phase 2 |
| Buloxibutid (C21) | Vicore Pharma | Phase 2b |
| AP02 | Avalyn Pharmaceuticals | Phase 2 |
| Gento-Fibrose Pulmonaire Program | Genoscience Pharma | Preclinical |
| SM001 (alidornase/Tigerase) | SarcoMed USA | Research |
| GNS-3545 (ROCK2 Inhibitor) | Genosco | Phase 1 |
| TG2 Inhibitor Program | Isterian Biotech | Preclinical |
| Taladegib (ENV-101) | Endeavor BioMedicines | Phase 2b |
| CAL101 | Calluna Pharma | Phase 2 |
| NVP-13 | Velvio | Pre-clinical |
| LASN01 | Lassen Therapeutics | Preclinical |